Astedt B
Dept. of Gynaecology and Obstetrics, University Hospital of Lund, Sweden.
Scand J Gastroenterol Suppl. 1987;137:22-5.
Tranexamic acid (AMCA) is a potent antifibrinolytic drug occurring in two isomeric forms; the antifibrinolytic potency resides in the transisomeric form. The main action of AMCA is blocking of the lysine-binding sites of the plasminogen molecule, which are of importance for the binding to fibrin. This prevents activation of plasminogen by plasminogen activator also absorbed to fibrin. AMCA can be administered perorally or intravenously and is excreted into the urine. It enters tissues and fluids in various concentrations and crosses the placenta. There is no evidence of a thrombogenic effect of AMCA, but in accordance with its action, it prolongs dissolution of fibrin deposits already formed. AMCA is a drug of high clinical value for the treatment of bleedings due to both systemic and local fibrinolysis.
氨甲环酸（AMCA）是一种有效的抗纤维蛋白溶解药物，有两种异构体形式；抗纤维蛋白溶解效力存在于反式异构体形式中。AMCA的主要作用是阻断纤溶酶原分子的赖氨酸结合位点，这些位点对于与纤维蛋白的结合很重要。这可防止已吸附在纤维蛋白上的纤溶酶原激活剂激活纤溶酶原。AMCA可口服或静脉给药，并经尿液排泄。它以不同浓度进入组织和体液，并可穿过胎盘。没有证据表明AMCA有血栓形成作用，但根据其作用机制，它会延长已形成的纤维蛋白沉积物的溶解时间。AMCA是一种具有很高临床价值的药物，可用于治疗全身性和局部性纤维蛋白溶解引起的出血。
